🚀 PSTV Rockets 100%: What’s Fueling Plus Therapeutics’ Wild Surge Today?

Biotech's favorite rollercoaster stock just hit warp speed—here's why traders are chasing the burn.

The Catalyst Drop

No FDA whispers or trial data leaks—just pure, unfiltered market adrenaline propelling PSTV into the stratosphere. Retail traders pile in like it's 2021, while shorts scramble for cover.

Volume Tells the Story

When a microcap does the Macarena on 10x average volume, you know this isn't your grandpa's value play. The tape shows algos and humans battling for control as bid stacks evaporate.

Reality Check Ahead?

Let's be real—this is the same sector where 'breakthrough' often means 'burn rate increase.' But today? Today belongs to the degenerates riding PSTV's parabolic arc straight to either glory or margin calls.

Confident Investing Starts Here:

• Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
• Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter

This approval covers the use of REYOBIQ as a potential treatment for pediatric patients with supratentorial recurrent, refractory, or progressive high-grade glioma (HGG) and ependymoma. The company will conduct a clinical trial of this, with the U.S. Department of Defense providing a $3 million grant to fund the study.

PSTV stock was up 103.69% in pre-market trading on Wednesday, following a 1.47% rally yesterday. However, the shares are down 83.74% year-to-date and have seen much volatility in 2025. This makes the stock a dangerous gambit not fit for risk-averse traders.

Is Plus Therapeutics Stock a Buy, Sell, or Hold?

Turning to Wall Street, the analysts’ consensus rating for Plus Therapeutics is Strong Buy, based on three Buy and one Hold rating over the past three months. With that comes an average PSTV stock price target of $10, representing a potential 5,247.59% upside for the shares.